Beam Therapeutics Inc. BEAM announced positive initial safety and efficacy data from a phase I/II study, which is evaluating its pipeline candidate, BEAM-302, for treating patients with alpha-1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback